Published in Arch Ophthalmol on March 01, 2010
Ocular Hypertension Treatment Study (OHTS) (OHTS) | NCT00000125
Aqueous Release to Treat IOP Spikes Post-cataract Surgery | NCT03500809
Glaucoma: genes, phenotypes, and new directions for therapy. J Clin Invest (2010) 1.39
Phase 3 randomized 3-month trial with an ongoing 3-month safety extension of fixed-combination brinzolamide 1%/brimonidine 0.2%. J Ocul Pharmacol Ther (2013) 1.08
Factors predicting the rate of functional progression in early and suspected glaucoma. Invest Ophthalmol Vis Sci (2012) 1.04
Perimetric indices as predictors of future glaucomatous functional change. Optom Vis Sci (2011) 1.04
Effect of treatment on the rate of visual field change in the ocular hypertension treatment study observation group. Invest Ophthalmol Vis Sci (2012) 1.03
Nonlinear, multilevel mixed-effects approach for modeling longitudinal standard automated perimetry data in glaucoma. Invest Ophthalmol Vis Sci (2013) 1.00
The rate of visual field change in the ocular hypertension treatment study. Invest Ophthalmol Vis Sci (2012) 0.98
Intraocular pressure magnitude and variability as predictors of rates of structural change in non-human primate experimental glaucoma. Exp Eye Res (2012) 0.97
Soluble guanylate cyclase α1-deficient mice: a novel murine model for primary open angle glaucoma. PLoS One (2013) 0.96
Sustained intraocular pressure reduction throughout the day with travoprost ophthalmic solution 0.004%. Clin Ophthalmol (2012) 0.94
Why Do People (Still) Go Blind from Glaucoma? Transl Vis Sci Technol (2015) 0.93
The effect of test variability on the structure-function relationship in early glaucoma. Graefes Arch Clin Exp Ophthalmol (2012) 0.91
Series length used during trend analysis affects sensitivity to changes in progression rate in the ocular hypertension treatment study. Invest Ophthalmol Vis Sci (2013) 0.91
Assessment of linear-scale indices for perimetry in terms of progression in early glaucoma. Vision Res (2011) 0.87
In vitro and in vivo experimental studies on trabecular meshwork degeneration induced by benzalkonium chloride (an American Ophthalmological Society thesis). Trans Am Ophthalmol Soc (2012) 0.85
Seasonal changes in visual field sensitivity and intraocular pressure in the ocular hypertension treatment study. Ophthalmology (2013) 0.84
Regulation of intraocular pressure by soluble and membrane guanylate cyclases and their role in glaucoma. Front Mol Neurosci (2014) 0.83
Intraocular pressure elevation and post-DSEK glaucoma after Descemet`s stripping endothelial keratoplasty. Graefes Arch Clin Exp Ophthalmol (2012) 0.82
Cup size predicts subsequent functional change in early glaucoma. Optom Vis Sci (2011) 0.81
Biomarkers of primary open-angle glaucoma. Expert Rev Ophthalmol (2010) 0.81
Clinical options for the reduction of elevated intraocular pressure. Ophthalmol Eye Dis (2012) 0.79
[Medicinal glaucoma therapy. What can we learn from large randomized clinical trials?]. Ophthalmologe (2013) 0.79
Twenty-four-hour pattern of intraocular pressure in untreated patients with ocular hypertension. Invest Ophthalmol Vis Sci (2013) 0.79
Treatment of ocular hypertension: Hamlet's Lament revisited. Arch Ophthalmol (2010) 0.78
Detection and measurement of clinically meaningful visual field progression in clinical trials for glaucoma. Prog Retin Eye Res (2016) 0.77
Detection and diagnosis of glaucoma: ocular imaging. Invest Ophthalmol Vis Sci (2012) 0.77
Effect of geranylgeranylacetone on the protection of retinal ganglion cells in a mouse model of normal tension glaucoma. Heliyon (2016) 0.76
An hypothesis on pressure transmission from anterior chamber to optic nerve. Med Hypotheses (2011) 0.76
Optical Quality and Related Factors in Ocular Hypertension: Preliminary Study. J Ophthalmol (2016) 0.75
Novel Pharmacologic Candidates for Treatment of Primary Open-Angle Glaucoma. Yale J Biol Med (2017) 0.75
Glaucoma Risk Alleles in the Ocular Hypertension Treatment Study. Ophthalmology (2016) 0.75
A Randomized Phase 1 Dose Escalation Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Trabodenoson in Healthy Adult Volunteers. J Ocul Pharmacol Ther (2016) 0.75
Reducing variability in visual field assessment for glaucoma through filtering that combines structural and functional information. Invest Ophthalmol Vis Sci (2014) 0.75
Risk of Ocular Hypertension in Adults with Noninfectious Uveitis. Ophthalmology (2017) 0.75
[Differentiation of ocular hypertension]. Ophthalmologe (2016) 0.75
[Arguments against pressure-lowering treatment of ocular hypertension. Prophylactic treatment is unnecessary]. Ophthalmologe (2011) 0.75
Statistical methods in cancer research. Volume II--The design and analysis of cohort studies. IARC Sci Publ (1987) 27.11
The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol (2002) 16.89
Number of people with glaucoma worldwide. Br J Ophthalmol (1996) 14.31
Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol (2002) 14.17
Racial variations in the prevalence of primary open-angle glaucoma. The Baltimore Eye Survey. JAMA (1991) 9.42
Optic nerve damage in human glaucoma. II. The site of injury and susceptibility to damage. Arch Ophthalmol (1981) 5.09
Racial differences in the cause-specific prevalence of blindness in east Baltimore. N Engl J Med (1991) 4.73
Prevalence of open-angle glaucoma and ocular hypertension in Latinos: the Los Angeles Latino Eye Study. Ophthalmology (2004) 3.66
The prevalence of glaucoma in a population-based study of Hispanic subjects: Proyecto VER. Arch Ophthalmol (2001) 3.31
The Ocular Hypertension Treatment Study: design and baseline description of the participants. Arch Ophthalmol (1999) 3.30
Incidence of open-angle glaucoma: the Barbados Eye Studies. The Barbados Eye Studies Group. Arch Ophthalmol (2001) 3.20
Analyzing survival curves at a fixed point in time. Stat Med (2007) 3.11
National survey of the prevalence and risk factors of glaucoma in St. Lucia, West Indies. Part I. Prevalence findings. Ophthalmology (1989) 2.78
Models of open-angle glaucoma prevalence and incidence in the United States. Invest Ophthalmol Vis Sci (1997) 2.75
Prevalence and causes of visual impairment in The Barbados Eye Study. Ophthalmology (2001) 2.70
Randomized clinical trials on medical treatment of glaucoma. Are they appropriate to guide clinical practice? Arch Ophthalmol (1993) 2.44
Validated prediction model for the development of primary open-angle glaucoma in individuals with ocular hypertension. Ophthalmology (2006) 2.28
Glaucoma and intraocular pressure in Jamaica. Am J Ophthalmol (1969) 1.90
Management of ocular hypertension: a cost-effectiveness approach from the Ocular Hypertension Treatment Study. Am J Ophthalmol (2006) 1.80
Falls in elderly patients with glaucoma. Arch Ophthalmol (1991) 1.74
Risk factors for incident nuclear opacities. Ophthalmology (2002) 1.72
Change points in the series of T4 counts prior to AIDS. Biometrics (1995) 1.58
Baseline visual field characteristics in the ocular hypertension treatment study. Ophthalmology (2002) 1.46
The Glaucoma Symptom Scale. A brief index of glaucoma-specific symptoms. Arch Ophthalmol (1998) 1.46
The Ocular Hypertension Treatment Study: reproducibility of cup/disk ratio measurements over time at an optic disc reading center. Am J Ophthalmol (2002) 1.27
Glaucoma care and conformance with preferred practice patterns. Examination of the private, community-based ophthalmologist. Ophthalmology (1996) 1.03
Open-angle glaucoma and mortality: The Barbados Eye Studies. Arch Ophthalmol (2008) 0.93
The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol (2002) 16.89
Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci U S A (2008) 16.54
Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol (2005) 15.61
The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma. Arch Ophthalmol (2002) 11.38
A computerized method of visual acuity testing: adaptation of the early treatment of diabetic retinopathy study testing protocol. Am J Ophthalmol (2003) 9.99
Diversity considerations in HIV-1 vaccine selection. Science (2002) 9.60
Effect of constraint-induced movement therapy on upper extremity function 3 to 9 months after stroke: the EXCITE randomized clinical trial. JAMA (2006) 9.55
Sexual behavior of HIV discordant couples after HIV counseling and testing. AIDS (2003) 8.05
Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. Nature (2013) 5.35
Renal structure in early autosomal-dominant polycystic kidney disease (ADPKD): The Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) cohort. Kidney Int (2003) 4.84
Free access to Landsat imagery. Science (2008) 4.75
Hybrid origin of SIV in chimpanzees. Science (2003) 3.75
Longitudinal course and neuropathologic outcomes in original vs revised MCI and in pre-MCI. Neurology (2006) 3.69
Prevalence of open-angle glaucoma and ocular hypertension in Latinos: the Los Angeles Latino Eye Study. Ophthalmology (2004) 3.66
Molecular epidemiology of human immunodeficiency virus type 1 transmission in a heterosexual cohort of discordant couples in Zambia. J Virol (2002) 3.58
Predictors of incomplete adherence, virologic failure, and antiviral drug resistance among HIV-infected adults receiving antiretroviral therapy in Tanzania. Clin Infect Dis (2007) 3.46
Cutting edge: TLR4 activation mediates liver ischemia/reperfusion inflammatory response via IFN regulatory factor 3-dependent MyD88-independent pathway. J Immunol (2004) 3.27
Comprehensive molecular diagnostics in autosomal dominant polycystic kidney disease. J Am Soc Nephrol (2007) 3.26
A group M consensus envelope glycoprotein induces antibodies that neutralize subsets of subtype B and C HIV-1 primary viruses. Virology (2006) 3.26
Controlled trial of transfusions for silent cerebral infarcts in sickle cell anemia. N Engl J Med (2014) 3.25
Risk of sudden visual loss following filtration surgery in end-stage glaucoma. Am J Ophthalmol (2005) 3.04
Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26. Nature (2013) 3.00
Streptococcal toxic shock syndrome caused by Streptococcus suis serotype 2. PLoS Med (2006) 2.99
Clinical trial of lutein in patients with retinitis pigmentosa receiving vitamin A. Arch Ophthalmol (2010) 2.78
Phenotypic properties of transmitted founder HIV-1. Proc Natl Acad Sci U S A (2013) 2.75
High-throughput isolation of immunoglobulin genes from single human B cells and expression as monoclonal antibodies. J Virol Methods (2009) 2.75
Ancient co-speciation of simian foamy viruses and primates. Nature (2005) 2.71
Effect of reclassification on the incidence of benign and malignant renal tumors. J Urol (2009) 2.67
The African Descent and Glaucoma Evaluation Study (ADAGES): design and baseline data. Arch Ophthalmol (2009) 2.59
Association between depression and functional vision loss in persons 20 years of age or older in the United States, NHANES 2005-2008. JAMA Ophthalmol (2013) 2.52
SIVcpz in wild chimpanzees. Science (2002) 2.45
Polyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individuals. J Virol (2011) 2.42
Influence of nitrous oxide anesthesia, B-vitamins, and MTHFR gene polymorphisms on perioperative cardiac events: the vitamins in nitrous oxide (VINO) randomized trial. Anesthesiology (2013) 2.39
Central corneal thickness and measured IOP response to topical ocular hypotensive medication in the Ocular Hypertension Treatment Study. Am J Ophthalmol (2004) 2.39
Magnetic resonance imaging evaluation of hepatic cysts in early autosomal-dominant polycystic kidney disease: the Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease cohort. Clin J Am Soc Nephrol (2005) 2.37
Reduction in intraocular pressure after cataract extraction: the Ocular Hypertension Treatment Study. Ophthalmology (2012) 2.35
The brain injury biomarker VLP-1 is increased in the cerebrospinal fluid of Alzheimer disease patients. Clin Chem (2008) 2.35
Rates of progression in mild cognitive impairment and early Alzheimer's disease. Neurology (2002) 2.34
Structures and receptor binding of hemagglutinins from human-infecting H7N9 influenza viruses. Science (2013) 2.34
Excess of early onset multiple myeloma in endometrial cancer probands and their relatives suggests common susceptibility. Gynecol Oncol (2007) 2.32
High-sensitivity cardiac troponin T in prediction and diagnosis of myocardial infarction and long-term mortality after noncardiac surgery. Am Heart J (2013) 2.30
In vivo molecular photoacoustic tomography of melanomas targeted by bioconjugated gold nanocages. ACS Nano (2010) 2.29
In vivo gp41 antibodies targeting the 2F5 monoclonal antibody epitope mediate human immunodeficiency virus type 1 neutralization breadth. J Virol (2009) 2.29
Validated prediction model for the development of primary open-angle glaucoma in individuals with ocular hypertension. Ophthalmology (2006) 2.28
Small bilaterian fossils from 40 to 55 million years before the cambrian. Science (2004) 2.25
Methods for a multisite randomized trial to investigate the effect of constraint-induced movement therapy in improving upper extremity function among adults recovering from a cerebrovascular stroke. Neurorehabil Neural Repair (2003) 2.22
Prevalence of open-angle glaucoma in Greece: the Thessaloniki Eye Study. Am J Ophthalmol (2007) 2.21
Cyst number but not the rate of cystic growth is associated with the mutated gene in autosomal dominant polycystic kidney disease. J Am Soc Nephrol (2006) 2.21
The effect of adverse housing and neighborhood conditions on the development of diabetes mellitus among middle-aged African Americans. Am J Epidemiol (2007) 2.17
Oxygen microscopy by two-photon-excited phosphorescence. Chemphyschem (2008) 2.17
Association between donor and recipient TCF7L2 gene polymorphisms and the risk of new-onset diabetes mellitus after liver transplantation in a Han Chinese population. J Hepatol (2012) 2.17
Does sex matter in glaucoma? Arch Ophthalmol (2004) 2.12
Hippocampal deformities in schizophrenia characterized by high dimensional brain mapping. Am J Psychiatry (2002) 2.11
Characterization of functional and phenotypic changes in anti-Gag vaccine-induced T cell responses and their role in protection after HIV-1 infection. Proc Natl Acad Sci U S A (2005) 2.10
A novel mechanism for vascular insulin resistance in normotensive young SHRs: hypoadiponectinemia and resultant APPL1 downregulation. Hypertension (2013) 2.10
Replication and compartmentalization of HIV-1 in kidney epithelium of patients with HIV-associated nephropathy. Nat Med (2002) 2.10
Detection of minor drug-resistant populations by parallel allele-specific sequencing. Nat Methods (2007) 2.09
Increased likelihood of glaucoma at the same screening intraocular pressure in subjects with pseudoexfoliation: the Thessaloniki Eye Study. Am J Ophthalmol (2009) 2.09
Differences in visual function and optic nerve structure between healthy eyes of blacks and whites. Arch Ophthalmol (2005) 2.09
Type 2 diabetes mellitus: the impact on colorectal adenoma risk in women. Am J Gastroenterol (2006) 2.07
US breast cancer mortality trends in young women according to race. Cancer (2014) 2.07
Vertical T cell immunodominance and epitope entropy determine HIV-1 escape. J Clin Invest (2012) 2.05
The Ocular Hypertension Treatment Study: topical medication delays or prevents primary open-angle glaucoma in African American individuals. Arch Ophthalmol (2004) 2.03
Quality of life in keratoconus. Am J Ophthalmol (2004) 2.03
DEG 10, an update of the database of essential genes that includes both protein-coding genes and noncoding genomic elements. Nucleic Acids Res (2013) 2.01
Time to activate lung cancer clinical trials and patient enrollment: a representative comparison study between two academic centers across the atlantic. J Clin Oncol (2010) 2.00
An international strategic plan to preserve and restore vision: four curricula of ophthalmic education. Am J Ophthalmol (2007) 1.99
Initial antibodies binding to HIV-1 gp41 in acutely infected subjects are polyreactive and highly mutated. J Exp Med (2011) 1.97
Glaucoma and its treatment: a review. Am J Health Syst Pharm (2005) 1.96
Aldehyde dehydrogenase 2 ameliorates acute cardiac toxicity of ethanol: role of protein phosphatase and forkhead transcription factor. J Am Coll Cardiol (2009) 1.91
Transmitted/founder and chronic subtype C HIV-1 use CD4 and CCR5 receptors with equal efficiency and are not inhibited by blocking the integrin α4β7. PLoS Pathog (2012) 1.88
Microsatellite instability and epigenetic inactivation of MLH1 and outcome of patients with endometrial carcinomas of the endometrioid type. J Clin Oncol (2007) 1.87
Pattern electroretinogram abnormality and glaucoma. Ophthalmology (2005) 1.82
Baseline topographic optic disc measurements are associated with the development of primary open-angle glaucoma: the Confocal Scanning Laser Ophthalmoscopy Ancillary Study to the Ocular Hypertension Treatment Study. Arch Ophthalmol (2005) 1.80
Further evaluation of docosahexaenoic acid in patients with retinitis pigmentosa receiving vitamin A treatment: subgroup analyses. Arch Ophthalmol (2004) 1.80
A centralized gene-based HIV-1 vaccine elicits broad cross-clade cellular immune responses in rhesus monkeys. Proc Natl Acad Sci U S A (2008) 1.80
Retrospective motion correction protocol for high-resolution anatomical MRI. Hum Brain Mapp (2006) 1.80
Management of ocular hypertension: a cost-effectiveness approach from the Ocular Hypertension Treatment Study. Am J Ophthalmol (2006) 1.80
Microbial biodegradation of polyaromatic hydrocarbons. FEMS Microbiol Rev (2008) 1.80